Angiodynamics

Eximo Medical Ltd. is an Israeli company specializing in hybrid catheter technology aimed at improving tissue resection in vascular and gastrointestinal endoluminal applications. Founded in 2012 and based in Modi'in-Maccabim-Re'ut, the company has developed the CatHI™, a proprietary single-use hybrid catheter that integrates optical fibers for delivering short laser pulses with a blunt mechanical knife. This innovative design enhances the safety and effectiveness of procedures, particularly in lead extraction and the treatment of peripheral artery disease, by minimizing the risk of vessel perforation. As of October 2019, Eximo Medical operates as a subsidiary of AngioDynamics, Inc.

RadiaDyne, established in 2007 and headquartered in Houston, Texas, is a medical diagnostic and device company. It specializes in designing and developing patient dose monitoring technology for cancer patients undergoing radiation treatments. The company's core offering is a radiation dose monitoring platform that ensures accurate dose readings, real-time pinpoint measurement, and utilizes proprietary delivery devices, aiming to enhance cancer patients' radiation therapy experience with reduced side effects and improved outcomes. As of 2018, RadiaDyne operates as a subsidiary of AngioDynamics, Inc.

Vortex Medical is a medical device company focused on the design, development and commercialization.

Navilyst Medical Inc., based in Marlborough, Massachusetts, specializes in the manufacturing of medical devices, particularly focusing on dialysis catheters, drainage catheters, fluid management products, and vascular accessories. Established in February 2008 from the Fluid Management and Vascular Access divisions of Boston Scientific, the company aims to enhance patient outcomes through its innovative products, which include the PASV Valve Technology and the Xcela Power Injectable PICCs. Navilyst operates a leading manufacturing facility in Glens Falls, New York, and distributes its products globally. The company's name reflects its mission to navigate and catalyze advancements in medical technology.

FlowMedica is a medical device company that specializes in intravascular systems for Targeted Renal Therapy, addressing renal conditions linked to cardiovascular disease, cancer, and surgical procedures. The company's flagship products include the Benephit CV Infusion System, which allows physicians to deliver therapeutic agents directly into the renal arteries via an infusion catheter, while facilitating simultaneous coronary procedures through a single access site in the femoral artery. Additionally, FlowMedica offers the Benephit XTMini Infusion System, designed for bilateral infusion to the kidneys, particularly beneficial for patients with smaller vascular anatomies. By providing a targeted approach to renal therapy, FlowMedica's devices serve as an effective alternative to traditional systemic intravenous infusion methods, enabling precise delivery in various clinical scenarios.

RITA Medical Systems develops, manufactures and markets innovative products for patients with solid cancerous or benign tumors. The proprietary RITA system uses radiofrequency energy to heat tissue to a high enough temperature to ablate it or cause cell death. While the Company's current focus is on liver cancer and metastatic bone cancer, the Company believes that its minimally invasive technology may in the future be applied to other types of tumors, including tumors of the lung, breast, uterus, prostate and kidney. The Company has received regulatory clearance in major markets worldwide, including the United States. In March 2000, RITA became the first radiofrequency ablation company to receive specific FDA clearance for unresectable liver lesions in addition to its previous general FDA clearance for the ablation of soft tissue. In October 2002, RITA again became the first company to receive specific FDA clearance, this time, for the palliation of pain associated with metastatic lesions involving bone. The Company has sold over 40,000 of its disposable devices throughout the world.